AstraZeneca PLCAZNNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank18
Year-over-Year Change
Year-over-year free cash flow growth rate
Percentile
P18
Within normal range
vs 5Y Ago
-5.8x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -69.05% |
| Q3 2025 | 204.03% |
| Q2 2025 | -55.45% |
| Q1 2025 | 68.24% |
| Q4 2024 | -3.60% |
| Q3 2024 | -16.22% |
| Q2 2024 | 174.35% |
| Q1 2024 | -38.56% |
| Q4 2023 | -35.84% |
| Q3 2023 | 80.97% |
| Q2 2023 | -25.74% |
| Q1 2023 | -9.82% |
| Q4 2022 | 1.37% |
| Q3 2022 | 158.01% |
| Q2 2022 | -75.43% |
| Q1 2022 | 309.86% |
| Q4 2021 | -33.90% |
| Q3 2021 | 75.33% |
| Q2 2021 | -58.77% |
| Q1 2021 | 17.20% |
| Q4 2020 | 11.91% |
| Q3 2020 | 1673.02% |
| Q2 2020 | 126.58% |
| Q1 2020 | -123.94% |
| Q4 2019 | 29.92% |
| Q3 2019 | 893.75% |
| Q2 2019 | 91.63% |
| Q1 2019 | -163.20% |
| Q4 2018 | 807.50% |
| Q3 2018 | 168.03% |
| Q2 2018 | 37.97% |
| Q1 2018 | -206.28% |
| Q4 2017 | -76.40% |
| Q3 2017 | 2433.33% |
| Q2 2017 | 72.73% |
| Q1 2017 | -122.52% |
| Q4 2016 | 196.40% |
| Q3 2016 | 154.27% |
| Q2 2016 | -192.45% |
| Q1 2016 | 2363.89% |